Efficacy and Safety Study of Megafer injection® in Pregnant Women

Efficacy and Safety Study of Injection Iron Sucrose in Pregnant Women with Iron Deficiency Anaemia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT201611037978N4

Enrollment

Registered

2016-11-18

Start date

2015-07-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Deficiency anemia. Iron Deficiency anemia, unspecified

Interventions

The total calculated dose was divided as 100 to 200 mg dose/day maximum once or twice in week. Firstly, 25mg (25ml) was infused over 30 minutes @12 drops /minute as a test dose and the remaining dose

Treatment - Drugs

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Pregnant Women in second or third trimester, Hb: = 8 g/dl and serum ferritin levels are below than normal Exclusion Criteria: Patient allergic to iron preparation or any other ingredient of Injection megafer.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Increase in Hb level after initiation of treatment, achievement of target haemoglobin. Timepoint: 2 & 4 weeks after first dose. Method of measurement: Haemoglobin testing.	—

Secondary

Measure	Time frame
Reported adverse events related to drug only. Timepoint: At every follow up visit. Method of measurement: Patient monitoring & Follow up calls to patients.	—

Countries

Pakistan

Contacts

Public ContactSalman Rahim

Nabiqasim Industries (Pvt) Ltd.

salman.rahim@nabiqasim.com0092213263631

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026